Alnylam Pharmaceuticals (NASDAQ:ALNY) Given a $145.00 Price Target at Piper Jaffray Companies

Piper Jaffray Companies set a $145.00 target price on Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report report published on Tuesday morning, TipRanks reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on ALNY. Stifel Nicolaus set a $116.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, September 3rd. Goldman Sachs Group restated a neutral rating and set a $80.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, May 23rd. Cowen lowered their price target on Alnylam Pharmaceuticals from $147.00 to $120.00 and set an outperform rating for the company in a research report on Wednesday, August 7th. Barclays reaffirmed a buy rating and set a $125.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 7th. Finally, UBS Group increased their price objective on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the stock a neutral rating in a report on Wednesday, September 4th. Six research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $116.13.

NASDAQ:ALNY traded up $1.90 during midday trading on Tuesday, reaching $86.17. 576,024 shares of the stock traded hands, compared to its average volume of 843,388. The company has a fifty day moving average of $79.70 and a 200 day moving average of $78.88. Alnylam Pharmaceuticals has a 12 month low of $60.27 and a 12 month high of $99.73. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.16 and a current ratio of 6.28. The stock has a market capitalization of $9.45 billion, a P/E ratio of -11.38 and a beta of 2.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative net margin of 848.70% and a negative return on equity of 56.42%. The business had revenue of $38.20 million for the quarter, compared to analyst estimates of $42.24 million. During the same quarter last year, the firm earned ($1.61) EPS. The company’s revenue was up 27.8% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals will post -8.21 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its position in Alnylam Pharmaceuticals by 41.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 225,148 shares of the biopharmaceutical company’s stock worth $16,412,000 after acquiring an additional 66,253 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 3.9% in the fourth quarter. Geode Capital Management LLC now owns 915,533 shares of the biopharmaceutical company’s stock worth $66,708,000 after purchasing an additional 34,770 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Alnylam Pharmaceuticals by 3.4% during the first quarter. Janus Henderson Group PLC now owns 25,243 shares of the biopharmaceutical company’s stock worth $2,360,000 after purchasing an additional 841 shares during the last quarter. Rhumbline Advisers boosted its holdings in Alnylam Pharmaceuticals by 2.5% during the first quarter. Rhumbline Advisers now owns 92,891 shares of the biopharmaceutical company’s stock worth $8,681,000 after purchasing an additional 2,295 shares during the last quarter. Finally, Comerica Bank grew its position in Alnylam Pharmaceuticals by 6.4% in the first quarter. Comerica Bank now owns 27,303 shares of the biopharmaceutical company’s stock valued at $2,482,000 after purchasing an additional 1,636 shares in the last quarter. Institutional investors and hedge funds own 94.26% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Recommended Story: Margin

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.